On June 30, 2026, in Wuxi, China, WuXi Biologics disclosed that it would be enhancing operations at two key facilities in Wuxi. This includes Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1). WuXi Biologics, a prominent CRDMO, renowned globally, is listed as 2269.HK. This move is aimed at bolstering the company's manufacturing capabilities and further solidifying its position in the industry.